低度恶性上皮性卵巢癌：放射科医生应了解的内容。
Low-grade epithelial ovarian cancer: what a radiologist should know.
作者信息
Elsherif Sherif, Javadi Sanaz, Viswanathan Chitra, Faria Silvana, Bhosale Priya
机构信息
1 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center , Houston, TX , USA.
出版信息
Br J Radiol. 2019 Mar;92(1095):20180571. doi: 10.1259/bjr.20180571. Epub 2019 Jan 31.
Abstract
Ovarian cancer accounts for the death of over 100,000 females every year and is the most lethal gynecological malignancy. Low-grade serous ovarian carcinoma (LGSOC) and high-grade serous ovarian carcinoma (HGSOC) have been found to represent two distinct entities based on their molecular differences, clinical course, and response to chemotherapy. Currently, all ovarian cancers are staged according to the revised staging system of the International Federation of Gynecology and Obstetrics (FIGO). Imaging plays an integral role in the diagnosis, staging, and follow-up of ovarian cancers. This review will be based on the two-tier grading system of epithelial ovarian cancers, with the main emphasis on serous ovarian cancer, and the role of imaging to characterize low-grade vs high-grade tumors and monitor disease recurrence during follow-up.
摘要
卵巢癌每年导致超过10万名女性死亡，是最致命的妇科恶性肿瘤。基于分子差异、临床病程及对化疗的反应，低级别浆液性卵巢癌（LGSOC）和高级别浆液性卵巢癌（HGSOC）已被发现代表两种不同的实体。目前，所有卵巢癌均根据国际妇产科联盟（FIGO）的修订分期系统进行分期。影像学在卵巢癌的诊断、分期及随访中发挥着不可或缺的作用。本综述将基于上皮性卵巢癌的两级分级系统，主要侧重于浆液性卵巢癌，以及影像学在鉴别低级别与高级别肿瘤及随访期间监测疾病复发方面的作用。
相似文献
1
Low-grade epithelial ovarian cancer: what a radiologist should know.低度恶性上皮性卵巢癌：放射科医生应了解的内容。
Br J Radiol. 2019 Mar;92(1095):20180571. doi: 10.1259/bjr.20180571. Epub 2019 Jan 31.
2
Changes in the Management and Prognosis of Ovarian Cancer Due to the New FIGO and WHO Classifications: A Case Series Observational Descriptive Study. Seven Years of Follow-up.由于新 FIGO 和 WHO 分类，卵巢癌的管理和预后发生变化：一项为期七年随访的病例系列观察描述性研究。
Int J Gynecol Cancer. 2018 Oct;28(8):1461-1470. doi: 10.1097/IGC.0000000000001331.
3
Current update on malignant epithelial ovarian tumors.恶性上皮性卵巢肿瘤的最新研究进展。
Abdom Radiol (NY). 2021 Jun;46(6):2264-2280. doi: 10.1007/s00261-021-03081-0. Epub 2021 Jun 5.
4
Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists.国际妇产科联盟（FIGO）修订的卵巢、输卵管及腹膜癌分期系统：对放射科医生的重要意义
Jpn J Radiol. 2016 Feb;34(2):117-24. doi: 10.1007/s11604-015-0513-3. Epub 2015 Dec 22.
5
Ultrasound characteristics of early-stage high-grade serous ovarian cancer.早期高级别浆液性卵巢癌的超声特征。
Am J Obstet Gynecol. 2021 Oct;225(4):409.e1-409.e8. doi: 10.1016/j.ajog.2021.04.262. Epub 2021 May 13.
6
BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.BRCA1、Ki67 和 β-连环蛋白免疫表达与低级别和高级别浆液性卵巢癌患者的分化、铂类药物反应或预后无关。
Int J Gynecol Cancer. 2018 Mar;28(3):437-447. doi: 10.1097/IGC.0000000000001205.
7
[Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum].[国际妇产科联盟（FIGO）目前关于卵巢癌、输卵管癌和腹膜癌的分期分类]
Ceska Gynekol. 2017 Summer;82(3):230-236.
8
Evolving population-based statistics for rare epithelial ovarian cancers.不断变化的基于人群的罕见上皮性卵巢癌统计数据。
Gynecol Oncol. 2020 Apr;157(1):3-11. doi: 10.1016/j.ygyno.2019.11.122. Epub 2020 Jan 15.
9
Low-grade serous ovarian carcinoma: A comprehensive literature review.低级别浆液性卵巢癌：一篇全面的文献综述。
Aust N Z J Obstet Gynaecol. 2020 Feb;60(1):27-33. doi: 10.1111/ajo.13105. Epub 2019 Dec 17.
10
Clinical Staging of Ovarian Cancer.卵巢癌的临床分期。
Methods Mol Biol. 2022;2424:3-10. doi: 10.1007/978-1-0716-1956-8_1.
引用本文的文献
1
Random forest-based model for the recurrence prediction of borderline ovarian tumor: clinical development and validation.基于随机森林的卵巢交界性肿瘤复发预测模型：临床开发与验证
J Cancer Res Clin Oncol. 2025 May 11;151(5):160. doi: 10.1007/s00432-025-06221-x.
2
LINC00704 facilitates cell proliferation, migration, and invasion via miR-323a-3p/SLC44A1 axis in epithelial ovarian cancer.LINC00704通过miR-323a-3p/SLC44A1轴促进上皮性卵巢癌的细胞增殖、迁移和侵袭。
Discov Oncol. 2025 Apr 29;16(1):640. doi: 10.1007/s12672-025-01866-z.
3
A predictive model for recurrence in patients with borderline ovarian tumor based on neural multi-task logistic regression.基于神经多任务逻辑回归的卵巢交界性肿瘤患者复发预测模型。
BMC Cancer. 2025 Feb 17;25(1):281. doi: 10.1186/s12885-025-13636-9.
4
Cryoglobulinemia Leading to the Diagnosis of Low Grade Serous Ovarian Carcinoma.冷球蛋白血症导致低度浆液性卵巢癌的诊断
J Community Hosp Intern Med Perspect. 2023 Nov 4;13(6):13-16. doi: 10.55729/2000-9666.1247. eCollection 2023.
5
Nomogram incorporating log odds of positive lymph nodes improves prognostic prediction for ovarian serous carcinoma: a real-world retrospective cohort study.纳入对数阳性淋巴结比值的列线图可改善卵巢浆液性癌的预后预测：一项真实世界回顾性队列研究。
BMJ Open. 2023 Oct 21;13(10):e074206. doi: 10.1136/bmjopen-2023-074206.
6
Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy.NT157抑制IRS1/2可通过使PI3K/AKT/mTOR通路失活并诱导自噬来抑制卵巢癌的恶性行为。
Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. doi: 10.1002/kjm2.12652. Epub 2023 Feb 2.
7
Current Update on PET/MRI in Gynecological Malignancies-A Review of the Literature.妇科恶性肿瘤中 PET/MRI 的最新研究进展：文献综述。
Curr Oncol. 2023 Jan 12;30(1):1077-1105. doi: 10.3390/curroncol30010083.
8
The Discrepancy between Preoperative Tumor Markers and Imaging Outcomes in Predicting Ovarian Malignancy.术前肿瘤标志物与影像学结果在预测卵巢恶性肿瘤方面的差异
Cancers (Basel). 2022 Nov 25;14(23):5821. doi: 10.3390/cancers14235821.
9
Low-Grade Serous Carcinoma of the Ovary: The Current Status.卵巢低级别浆液性癌：现状
Diagnostics (Basel). 2022 Feb 10;12(2):458. doi: 10.3390/diagnostics12020458.
10
lncRNA SNHG15 Promotes Ovarian Cancer Progression through Regulated CDK6 via Sponging miR-370-3p.lncRNA SNHG15 通过海绵吸附 miR-370-3p 调控 CDK6 促进卵巢癌细胞的进展。
Biomed Res Int. 2021 Oct 25;2021:9394563. doi: 10.1155/2021/9394563. eCollection 2021.
本文引用的文献
1
Low-grade Serous Ovarian Carcinoma.低级别浆液性卵巢癌
Geburtshilfe Frauenheilkd. 2018 Oct;78(10):972-976. doi: 10.1055/a-0717-5411. Epub 2018 Oct 19.
2
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation.达拉非尼和曲美替尼治疗对一名接受过大量治疗的BRAF V600E突变低级别浆液性卵巢癌患者产生显著临床反应。
Gynecol Oncol Rep. 2018 Sep 10;26:41-44. doi: 10.1016/j.gore.2018.09.002. eCollection 2018 Nov.
3
Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses.基于简化MRI方案的ADNEX MR评分系统对附件肿块评估的准确性。
Diagn Interv Radiol. 2018 Mar-Apr;24(2):63-71. doi: 10.5152/dir.2018.17378.
4
Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age.I 期上皮性卵巢癌患者的肿瘤生育学：保留生育功能手术治疗育龄期年轻女性。
World J Surg Oncol. 2017 Aug 15;15(1):154. doi: 10.1186/s12957-017-1222-4.
5
Preliminary application of multiple parameters spectral CT in the diagnosis of ovarian cancer.多参数光谱CT在卵巢癌诊断中的初步应用
Medicine (Baltimore). 2017 Aug;96(32):e7786. doi: 10.1097/MD.0000000000007786.
6
Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).低级别浆液性卵巢癌（LGSC）中下丘脑-垂体-性腺轴相关激素受体的表达
J Ovarian Res. 2017 Jan 25;10(1):7. doi: 10.1186/s13048-016-0300-5.
7
Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.妇科疾病影像学（十二）：侵袭性和非侵袭性恶性浆液性卵巢肿瘤的临床和超声特征。
Ultrasound Obstet Gynecol. 2017 Dec;50(6):788-799. doi: 10.1002/uog.17414. Epub 2017 Nov 2.
8
Potential Application of Dual-Energy CT in Gynecologic Cancer: Initial Experience.
AJR Am J Roentgenol. 2017 Mar;208(3):695-705. doi: 10.2214/AJR.16.16227. Epub 2017 Jan 11.
9
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment.上皮性卵巢癌的分子特征：对诊断和治疗的意义。
Int J Mol Sci. 2016 Dec 15;17(12):2113. doi: 10.3390/ijms17122113.
10
Low-grade serous ovarian cancer: A review.低度浆液性卵巢癌：综述
Gynecol Oncol. 2016 Nov;143(2):433-438. doi: 10.1016/j.ygyno.2016.08.320. Epub 2016 Aug 28.
Zotero 插件